Aaron Klaiber
Doctoral researcher at the University of Basel
Data updated
Research Footprint
Aaron Klaiber appears in 11 tracked papers (2022–2026), most studied alongside LSD, Mescaline and DMT, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants (138 citations).
Frequent co-authors: Matthias Liechti, Anna Becker and Dominik Klaiber.
Background & Research
Aaron Klaiber is a doctoral researcher affiliated with the University of Basel’s psychiatry/psychology research environment. He appears as a co-author on several recent controlled clinical studies of classic psychedelics and MDMA in healthy participants, including work on DMT, mescaline, LSD, and MDMA combinations. His publication trail indicates involvement in experimental psychopharmacology and human psychedelic research at the University of Basel.
Key Impact
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Collaboration Network
21 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Aaron Klaiber is associated with.